• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ZIMMER BIOMET / SEIKAGAKU CORPORATION, TAKAHAGI PLANT GEL-ONE CROSS-LINKED HYALURONATE KNEE INJECTION; ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ZIMMER BIOMET / SEIKAGAKU CORPORATION, TAKAHAGI PLANT GEL-ONE CROSS-LINKED HYALURONATE KNEE INJECTION; ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Device Problem Patient-Device Incompatibility (2682)
Patient Problems Fall (1848); Fatigue (1849); Hypersensitivity/Allergic reaction (1907); High Blood Pressure/ Hypertension (1908); Low Blood Pressure/ Hypotension (1914); Memory Loss/Impairment (1958); Muscle Weakness (1967); Pain (1994); Red Eye(s) (2038); Blurred Vision (2137); Hot Flashes/Flushes (2153); Chills (2191); Dizziness (2194); Discomfort (2330); Numbness (2415); Diaphoresis (2452); Pallor (2468); Low Oxygen Saturation (2477); Balance Problems (4401); Paresthesia (4421); Unspecified Respiratory Problem (4464); Decreased Appetite (4569)
Event Date 04/26/2022
Event Type  Injury  
Event Description
My husband experienced a severe reaction to the gel-one knee injection within an hour and half of receiving the second gel-one injection-(first one given approximately one year before) on (b)(6) 2022.On (b)(6) 2022: severe symptoms began shortly after receiving gel-one knee injection to left knee.On (b)(6) 2022 with noted knee discomfort followed by several severe episodes of uncontrolled physical spinning with collapse, unable to move or get up with strong pulling sensation to his left side, profuse sweating alternate w chills, high bp and weakness until 911 was called: patient was admitted and finally discharged on (b)(6) 2022 despite continued high blood pressure as no findings in ordered testing.On (b)(6) 2022: symptoms of concern remained with knee pain, dizziness, light sensitivity, difficulty w focus/vision, fatigue, frequent bouts of high bp up to 201/125 or similar between meds, forgetfulness, often feeling cold on (b)(6) 2022 incident: sudden facial flushing, eyes red, metallic taste in mouth with numbness, feeling of throat closing, tingling sensation of hands-treated with liquid benadryl; on (b)(6) 2022: symptoms continue with fluctuating low blood pressure with readings 80/50 range follow by low normal range; temperature regulation issue-difficulty overheating alternating feeling cold, light sensitivity/vision problems, easily fatigue, little appetite, forgetfulness; frequent paleness in face and hands; on (b)(6) 2022- present: symptoms of blood pressure regulation with dangerous levels of fluctuations and temperature regulation, often with low oxygen levels continue to be ongoing as well as still debilitating fatigue, knee pain, and intermittent allergic reaction symptoms.Note: patient attended all neurological testing in which no findings, rheumatologist discharged patient after knee continued to worsen and referred to orthopedic surgeon which scheduled full knee replacement: patient has not been able to work since the event or do normal life activities; he has also been seen by pcp multiple times however no medications have helped with the concerning symptoms.Fda safety report id# (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GEL-ONE CROSS-LINKED HYALURONATE KNEE INJECTION
Type of Device
ACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
ZIMMER BIOMET / SEIKAGAKU CORPORATION, TAKAHAGI PLANT
MDR Report Key15632976
MDR Text Key302093694
Report NumberMW5112729
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Patient Family Member or Friend
Type of Report Initial
Report Date 10/15/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Was Device Available for Evaluation? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received10/18/2022
Patient Sequence Number1
Treatment
CRESTOR; DAILY VITAMIN; LISINOPRIL; PROPANOL; TREXIMET
Patient Outcome(s) Required Intervention; Hospitalization; Life Threatening; Disability;
Patient Age61 YR
Patient SexMale
Patient Weight75 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-